Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 3/20 | 0.56 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.56 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 3/20 | 0.48 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyrophosphoric Acid SCHEMBL3490171 | 1.00 | GABBR2 (0.56) | GABBR2GABBR1GABRR1FDPSBLM | |
| Pyrophosphoric Acid SCHEMBL1665877 | 1.00 | GABBR2 (0.56) | GABBR2GABBR1GABRR1FDPSBLM | |
| Pyrophosphoric Acid SCHEMBL28346644 | 0.93 | GABBR2 (0.54) | GABBR2GABBR1GABRR1FDPSLPAR3 | |
| Hexadecylamine SCHEMBL28476428 | 0.91 | DNM1 (0.56) | GABBR2GABBR1GABRR1FDPSLPAR3 | |
| Hexadecylamine SCHEMBL28476430 | 0.91 | DNM1 (0.56) | GABBR2GABBR1GABRR1FDPSLPAR3 | |
| Pyrophosphoric Acid SCHEMBL9547111 | 0.91 | DNM1 (0.56) | GABBR2GABBR1GABRR1FDPSLPAR3 | |
| Pyrophosphoric Acid SCHEMBL9547103 | 0.91 | DNM1 (0.56) | GABBR2GABBR1GABRR1FDPSLPAR3 | |
| Pyrophosphoric Acid SCHEMBL6261145 | 0.87 | FDPS (0.56) | GABBR2GABBR1GABRR1FDPSBLM | |
| Peroxymonophosphate SCHEMBL27906960 | 0.86 | GABBR2 (0.56) | GABBR2GABBR1GABRR1FDPSBLM | |
| Pyrophosphoric Acid SCHEMBL14953208 | 0.86 | GABBR2 (0.47) | GABBR2GABBR1GABRR1FDPSBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025264831-A1 | METHODS FOR INCREASING SEQUENCING QUALITY OF GC-RICH REGIONS | ILLUMINA, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264836-A1 | METHODS FOR INCREASING SEQUENCING QUALITY OF GC-RICH REGIONS | ILLUMINA, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-3743517-B1 | SEQUENCING ADDITIVE | QIAGEN SCIENCES LLC (US) | 2024-03-06 | — | — | EP | disclosed |
| US-11821032-B2 | DNA sequencing reaction additive | IsoPlexis Corporation (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230340583-A1 | DNA SEQUENCING REACTION ADDITIVE | IsoPlexis Corporation | 2023-10-26 | — | — | US | disclosed |
| US-11548909-B2 | Methods of using nucleotide analogues | IsoPlexis Corporation (US) | 2023-01-10 | — | — | US | disclosed |
| US-20220315995-A1 | THIOL-CONTAINING CLEAVE REAGENTS AND OXIDATIVE WASH | QIAGEN WALTHAM, INC. | 2022-10-06 | — | — | US | disclosed |
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | QIAGEN SCIENCES, LLC | 2022-05-26 | — | — | US | disclosed |
| US-11117921-B2 | Methods for synthesizing nucleotide analogues with disulfide linkers | IsoPlexis Corporation (US) | 2021-09-14 | — | — | US | disclosed |
| US-11046726-B2 | Nucleotide analogues | QIAGEN SCIENCES, LLC (US) | 2021-06-29 | — | — | US | disclosed |
| US-6309836-B1 | CONTACTING TARGET NUCLEIC ACID WITH PRIMER SO PRIMER ANNEALS TO NUCLEIC ACID IN SEQUENCE SPECIFIC MANNER, INCORPORATING HYDROCARBYLDITHIOMETHYL-MODIFIED NUCLEOTIDE INTO PRIMER, DETECTING MODIFIED NUCLEOTIDE, IDENTIFYING SEQUENCE OF BASE | ILLUMINA, INC. | 2001-10-30 | — | — | US | disclosed |
| WO-2001025247-A1 | COMPOUNDS FOR PROTECTING HYDROXYLS AND METHODS FOR THEIR USE | QUIATECH AB (SE) | 2001-04-12 | — | — | WO | disclosed |
| EP-0831846-A1 | CAPPED SYNTHETIC RNA, ANALOGS, AND APTAMERS | Merck & Co., Inc. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1998011120-A1 | A METHOD OF NUCLEIC ACID SEQUENCING | DUKE UNIVERSITY (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1996041812-A1 | OLIGONUCLEOTIDE PHOSPHORYLATION METHOD AND PRODUCTS | ISIS INNOVATION LIMITED (GB) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996040159-A1 | CAPPED SYNTHETIC RNA, ANALOGS, AND APTAMERS | MERCK & CO., INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995009248-A1 | METHODS AND COMPOSITIONS FOR EFFICIENT NUCLEIC ACID SEQUENCING | ARCH DEVELOPMENT CORP. (US) | 1995-04-06 | — | — | WO | disclosed |
| WO-1995006752-A1 | A METHOD OF NUCLEIC ACID SEQUENCING | DUKE UNIVERSITY (US) | 1995-03-09 | — | — | WO | disclosed |
| WO-1993023415-A1 | CHEMICAL SYNTHESIS OF 2',3'-DIDEOXYNUCLEOSIDE 5'-(α-THIO) TRIPHOSPHATES | UNITED STATES BIOCHEMICAL CORPORATION (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993023416-A1 | CHEMICAL SYNTHESIS OF 2',3'-DIDEOXYNUCLEOSIDE 5'-TRIPHOSPHATES | UNITED STATES BIOCHEMICAL CORPORATION (US) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11548909-B2 | Methods of using nucleotide analogues | NT5C3B, SAMHD1, RNGTT | GABBR2 4039/4885GABBR1 4463/4885GABRR1 4340/4885 |
| US-11046726-B2 | Nucleotide analogues | NT5C3B, SAMHD1, DUT | GABBR2 4379/4885GABBR1 4652/4885GABRR1 4657/4885 |
| US-20220162251-A1 | NUCLEOTIDE ANALOGUES | NT5C3B, SAMHD1, DUT | GABBR2 4379/4885GABBR1 4652/4885GABRR1 4657/4885 |
| US-20220315995-A1 | THIOL-CONTAINING CLEAVE REAGENTS AND OXIDATIVE WASH | SAMHD1, UNG, RNGTT | GABBR2 4571/4885GABBR1 4669/4885GABRR1 4706/4885 |
| US-11821032-B2 | DNA sequencing reaction additive | RNGTT, NSUN2, NT5C3B | GABBR2 3755/4885GABBR1 3758/4885GABRR1 4783/4885 |
| US-20230340583-A1 | DNA SEQUENCING REACTION ADDITIVE | RNGTT, NSUN2, NT5C3B | GABBR2 3755/4885GABBR1 3758/4885GABRR1 4783/4885 |
| US-11117921-B2 | Methods for synthesizing nucleotide analogues with disulfide linkers | RNGTT, NT5C3B, DUT | GABBR2 4251/4885GABBR1 4629/4885GABRR1 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.